Speakers
Session
Dr Susan Galbraith has over 23 years of Oncology pharmaceutical development experience. She joined AstraZeneca in 2010 and became EVP of Oncology Haematology R&D in 2021. She has been responsible for transforming the productivity and scientific output from AstraZeneca Oncology Haematology R&D. Susan has helped develop 13 approved medicines including olaparib, osimertinib, acalabrutinib, durvalumab, selumetinib, savolitinib, tremelimumab, trastuzumab deruxtecan, capivasertib, and datopotamb deruxtecan. In her prior role at Bristol-Myers Squibb she was instrumental in the development of nivolumab, ipilimumab and elotuzumab.
Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the Institute of Cancer Research (ICR). From 2021 to 2024 she served on the Board of Directors of the American Association of Cancer Research (AACR) and currently serves on the European Association of Cancer Research (EACR) Advisory Council.
Susan trained as a Clinical Oncologist in the United Kingdom. She studied Medicine at Manchester and Cambridge Universities. She was admitted to Membership of the Royal College of Physicians in 1992 and then trained in Clinical Oncology in London. She gained Fellowship of the Royal College of Radiologists in 1997. She then completed a PhD at the University of London involving translational work on a vascular-targeting agent. In recognition of her contributions to oncology drug development, she was awarded an honorary Doctorate of Medical Science from the ICR in 2017, admitted to the Fellowship of the Academy of Medical Sciences in 2018 and elected to the Academy of the AACR in 2024.